Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Ibsrela (tenapanor) is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Tenapanor significantly reduced serum phosphorus levels in hemodialysis patients with hyperphosphatemia by a mean difference of 1.79 mg/dl compared to placebo.
• Tenapanor was superior to placebo for improving abdominal bloating in IBS-C patients, but indirect comparisons revealed no significant differences in efficacy when compared to other drugs like Linaclotide, Lubiprostone, and Tegaserod.
• Specific comparative efficacy data for Tenapanor in treating chronic idiopathic constipation were not detailed, though it was included in the network meta-analysis.
• Diarrhea, gastrointestinal adverse events (AEs), and drug-related AEs were more severe in patients treated with tenapanor compared to placebo.
• The safety profile of tenapanor was not specifically detailed in two of the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.